Viking Therapeutics (VKTX) Free Cash Flow (2014 - 2026)
Viking Therapeutics (VKTX) reported Free Cash Flow of -$114.0 million for Q1 2026, down 117.8% on a YoY basis from $640.4 million in Q1 2025, and down 33.63% sequentially from -$85.3 million in Q4 2025.
Viking Therapeutics (VKTX) Free Cash Flow (2014 - 2026) Analysis & Trends
Viking Therapeutics (VKTX) has 13 years of Free Cash Flow data on file, last reported at -$114.0 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 117.8% year-over-year to -$114.0 million; the trailing twelve-month figure through Mar 2026 stood at -$340.3 million (down 154.0% YoY), and the FY2025 full-year result was -$278.7 million, down 217.45% from the prior year.
- Free Cash Flow declined to -$114.0 million in Q1 2026, from -$85.3 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$6.1 million in Q1 2024 to a low of -$114.0 million in Q1 2026.
- A 5-year average of -$35.4 million and a median of -$22.0 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow soared 75.11% in 2024 and slumped 753.13% in 2025, its largest moves.
- Tracing VKTX's Free Cash Flow over 5 years: stood at -$10.9 million in 2022, then slumped by 61.45% to -$17.6 million in 2023, then tumbled by 76.76% to -$31.2 million in 2024, then sank by 173.53% to -$85.3 million in 2025, then plunged by 33.63% to -$114.0 million in 2026.
- Business Quant data shows VKTX's Free Cash Flow at -$114.0 million in Q1 2026, -$85.3 million in Q4 2025, and -$94.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Viking Therapeutics | 4.09 Bn | 4.09 Bn | - | -113.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -113.98 Mn |
| Mar 31, 2026 | -113.98 Mn |
| Dec 31, 2025 | -85.29 Mn |
| Dec 31, 2025 | -85.29 Mn |
| Sep 30, 2025 | -94.00 Mn |
| Sep 30, 2025 | -94.00 Mn |
| Jun 30, 2025 | -47.06 Mn |
| Jun 30, 2025 | -47.06 Mn |
| Mar 31, 2025 | -52.33 Mn |
| Mar 31, 2025 | -52.33 Mn |
| Dec 31, 2024 | -31.18 Mn |
| Dec 31, 2024 | -31.18 Mn |
| Sep 30, 2024 | -21.96 Mn |
| Sep 30, 2024 | -21.96 Mn |
| Jun 30, 2024 | -28.51 Mn |
| Jun 30, 2024 | -28.51 Mn |
| Mar 31, 2024 | -6.13 Mn |
| Mar 31, 2024 | -6.13 Mn |
| Dec 31, 2023 | -17.64 Mn |
| Dec 31, 2023 | -17.64 Mn |